Dong R[au] - Search Results

Year	Number of Results
1980	1
1983	1
1985	1
1986	4
1987	1
1988	2
1990	1
1991	1
1992	8
1993	3
1994	5
1995	3
1996	4
1997	8
1998	4
1999	4
2000	8
2001	10
2002	8
2003	13
2004	19
2005	26
2006	38
2007	29
2008	25
2009	37
2010	47
2011	56
2012	68
2013	89
2014	126
2015	146
2016	129
2017	146
2018	159
2019	222
2020	261
2021	303
2022	31

1

Single-Cell Characterization of Malignant Phenotypes and Developmental Trajectories of Adrenal Neuroblastoma.

Dong R, Yang R, Zhan Y, Lai HD, Ye CJ, Yao XY, Luo WQ, Cheng XM, Miao JJ, Wang JF, Liu BH, Liu XQ, Xie LL, Li Y, Zhang M, Chen L, Song WC, Qian W, Gao WQ, Tang YH, Shen CY, Jiang W, Chen G, Yao W, Dong KR, Xiao XM, Zheng S, Li K, Wang J. Dong R, et al. Cancer Cell. 2020 Nov 9;38(5):716-733.e6. doi: 10.1016/j.ccell.2020.08.014. Epub 2020 Sep 17. Cancer Cell. 2020. PMID: 32946775 Free article.

2

PROTAC: A promising technology for cancer treatment.

Zhou X, Dong R, Zhang JY, Zheng X, Sun LP. Zhou X, et al. Among authors: dong r. Eur J Med Chem. 2020 Oct 1;203:112539. doi: 10.1016/j.ejmech.2020.112539. Epub 2020 Jul 15. Eur J Med Chem. 2020. PMID: 32698111 Review.

3

Berberine in the treatment of ulcerative colitis: A possible pathway through Tuft cells.

Xiong X, Cheng Z, Wu F, Hu M, Liu Z, Dong R, Chen G. Xiong X, et al. Among authors: dong r. Biomed Pharmacother. 2021 Feb;134:111129. doi: 10.1016/j.biopha.2020.111129. Epub 2020 Dec 24. Biomed Pharmacother. 2021. PMID: 33348308 Free article. Review.

4

Hepatic stellate cell reprogramming via exosome-mediated CRISPR/dCas9-VP64 delivery.

Luo N, Li J, Chen Y, Xu Y, Wei Y, Lu J, Dong R. Luo N, et al. Among authors: dong r. Drug Deliv. 2021 Dec;28(1):10-18. doi: 10.1080/10717544.2020.1850917. Drug Deliv. 2021. PMID: 33336604 Free PMC article.

5

Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer.

Zhang J, Dong R, Shen L. Zhang J, et al. Among authors: dong r. Chin J Cancer Res. 2020 Apr;32(2):263-270. doi: 10.21147/j.issn.1000-9604.2020.02.13. Chin J Cancer Res. 2020. PMID: 32410803 Free PMC article.

6

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.

Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, Xia YZ, Kong LY. Dong RF, et al. Pharmacol Res. 2021 May;167:105583. doi: 10.1016/j.phrs.2021.105583. Epub 2021 Mar 26. Pharmacol Res. 2021. PMID: 33775864 Review.

7

[Retracted] Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.

Yang Q, Zhang S, Kang M, Dong R, Zhao J. Yang Q, et al. Among authors: dong r. Oncol Rep. 2021 Sep;46(3):193. doi: 10.3892/or.2021.8144. Epub 2021 Jul 19. Oncol Rep. 2021. PMID: 34278510 Free PMC article.

8

Hereditäre Ichthyose und Pilzinfektion: aktuelle Daten zu Pathogenese und Behandlungsstrategien.

Miao H, Dong R, Zhang S, Yang L, Liu Y, Wang T. Miao H, et al. Among authors: dong r. J Dtsch Dermatol Ges. 2021 Mar;19(3):341-351. doi: 10.1111/ddg.14389_g. J Dtsch Dermatol Ges. 2021. PMID: 33709589 Review. German.

9

[Retracted] Polyphenol‑rich extract of Saliva chinensis exhibits anticancer activity in different cancer cell lines, and induces cell cycle arrest at the G0/G1‑phase, apoptosis and loss of mitochondrial membrane potential in pancreatic cancer cells.

Zhao Q, Huo XC, Sun FD, Dong RQ. Zhao Q, et al. Among authors: dong rq. Mol Med Rep. 2021 Jun;23(6):462. doi: 10.3892/mmr.2021.12101. Epub 2021 Apr 21. Mol Med Rep. 2021. PMID: 33880580 Free PMC article.

10

Interventional Treatment for Cholangiocarcinoma.

Li H, Chen L, Zhu GY, Yao X, Dong R, Guo JH. Li H, et al. Among authors: dong r. Front Oncol. 2021 Jun 29;11:671327. doi: 10.3389/fonc.2021.671327. eCollection 2021. Front Oncol. 2021. PMID: 34268114 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results